The results of this research demonstrated that conjugating a GRP78 inhibitor to the radiotherapeutic [177Lu]Lu–iPSMA improves cytosolic internalization in prostate cancer cells, compared to the monomer [177Lu]Lu–iPSMA. Here, HSPA5 is linked to prostate carcinoma.